Clinical Trial Update: Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA [Phase 2]

View source ↗

Summary

Phase II study of AZD9291 in advanced non-small cell lung cancer with EGFR and T790M mutations detected in plasma Ct-DNA is in phase 2 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN